Read this manager's filing book
Disclosed positions
Soleus Capital Management, L.P.: source evidence dated 2026-08-12T03:59:59.999Z.
- Issuer
- KRYSTAL BIOTECH INC
- Ticker
- KRYS
- Class
- COM
- Reported value
- $349,092,534
- Reported amount
- 939,254
- Unit
- SH
- Option
- None
The displayed owner or issuer and source fields identify the receipt to verify; keep reporting and availability dates separate.
What was reported for this quarter?
13F positions are dated quarter-end holdings, with later publication and possible amendments. Read report period and availability before calling them current.
SEC 13F-HR: 0001802630-26-000005Open the effective filing receipt and inspect shares, value and any put/call classification separately.
Browse institutional filings
Open the effective filing receipt and inspect shares, value and any put/call classification separately.
Browse institutional filingsKeep reporting dates and units beside the answer, and inspect its original citations.
Disclosed positions
See the complete disclosed positions
Scroll sideways to compare all columns. Select a heading to sort.
| KRYSTAL BIOTECH INC | KRYS | COM | $349,092,534 | 939,254 | SH | None |
| CELCUITY INC | CELC | COM | $178,305,749 | 1,704,318 | SH | None |
| TG THERAPEUTICS INC | TGTX | COM | $160,858,551 | 2,927,895 | SH | None |
| INSULET CORP | PODD | COM | $159,710,250 | 1,049,000 | SH | None |
| NOVOCURE LTD | NVCR | ORD SHS | $150,188,025 | 9,913,401 | SH | None |
| UNITED THERAPEUTICS CORP DEL | UTHR | COM | $122,229,804 | 225,587 | SH | None |
| INSPIRE MED SYS INC | INSP | COM | $86,161,360 | 1,931,436 | SH | None |
| RIGEL PHARMACEUTICALS INC | RIGL | COM | $72,117,876 | 1,843,504 | SH | None |
| ANI PHARMACEUTICALS INC | ANIP | COM | $71,833,173 | 867,760 | SH | None |
| BETA BIONICS INC | BBNX | COM | $68,849,498 | 4,393,714 | SH | None |
| VERICEL CORP | VCEL | COM | $64,917,672 | 1,459,152 | SH | None |
| PRAXIS PRECISION MEDICINES I | PRAX | COM NEW | $59,430,916 | 177,517 | SH | None |
| GERON CORP | GERN | COM | $54,795,084 | 42,808,659 | SH | None |
| ALKERMES PLC | ALKS | SHS | $53,927,659 | 1,029,252 | SH | None |
| ERASCA INC | ERAS | COM | $49,464,000 | 2,700,000 | SH | None |
| NEUROPACE INC | NPCE | COM | $46,257,729 | 2,911,122 | SH | None |
| PROGYNY INC | PGNY | COM | $46,185,660 | 1,602,000 | SH | None |
| INDIVIOR PHARMACEUTICALS INC | INDV | COM | $43,655,920 | 1,064,000 | SH | None |
| PARABILIS MEDICINES INC | PBLS | COM | $40,098,966 | 1,465,070 | SH | None |
| EDAP TMS S A | FOCL | SPONSORED ADR | $37,861,936 | 7,309,254 | SH | None |
| GLOBUS MED INC | GMED | CL A | $37,049,527 | 468,922 | SH | None |
| ARCUS BIOSCIENCES INC | RCUS | COM | $36,032,193 | 1,168,738 | SH | None |
| SYNDAX PHARMACEUTICALS INC | SNDX | COM | $35,588,933 | 1,628,039 | SH | None |
| NURIX THERAPEUTICS INC | NRIX | COM | $35,544,854 | 1,465,163 | SH | None |
| LEGEND BIOTECH CORP | LEGN | SPONSORED ADS | $34,800,400 | 1,205,000 | SH | None |
| JADE BIOSCIENCES INC | JBIO | COM NEW | $34,456,332 | 1,550,690 | SH | None |
| UNITEDHEALTH GROUP INC | UNH | COM | $33,250,400 | 80,000 | SH | None |
| AVALO THERAPEUTICS INC | AVTX | COM NEW | $30,583,993 | 1,654,978 | SH | None |
| UROGEN PHARMA LTD | URGN | COM | $30,537,008 | 829,810 | SH | None |
| MBX BIOSCIENCES INC | MBX | COM | $28,443,401 | 515,279 | SH | None |
| PALISADE BIO INC | PALI | COM | $27,303,106 | 13,063,687 | SH | None |
| PHARVARIS N V | PHVS | COM | $25,274,764 | 730,907 | SH | None |
| ORGANOGENESIS HLDGS INC | ORGO | COM | $24,642,511 | 10,140,951 | SH | None |
| SUPERNUS PHARMACEUTICALS | SUPN | COM | $24,185,200 | 520,000 | SH | None |
| PROCEPT BIOROBOTICS CORP | PRCT | COM | $22,647,740 | 1,003,000 | SH | None |
| TANGO THERAPEUTICS INC | TNGX | COM | $22,163,340 | 709,000 | SH | None |
| INHIBIKASE THERAPEUTICS INC | IKT | COM NEW | $22,076,250 | 10,875,000 | SH | None |
| TREVI THERAPEUTICS INC | TRVI | COM | $21,999,876 | 1,179,618 | SH | None |
| BIOMARIN PHARMACEUTICAL INC | BMRN | COM | $21,490,230 | 375,572 | SH | None |
| LIVANOVA PLC | LIVN | SHS | $20,965,114 | 254,957 | SH | None |
| ARGENX SE | ARGX | SPONSORED ADR | $18,513,650 | 19,955 | SH | None |
| NUVECTIS PHARMA INC | NVCT | COM | $18,390,000 | 1,000,000 | SH | None |
| CAPRICOR THERAPEUTICS INC | CAPR | COM NEW | $18,342,627 | 761,737 | SH | None |
| EDGEWISE THERAPEUTICS INC | EWTX | COM | $18,319,620 | 450,889 | SH | None |
| PRELUDE THERAPEUTICS INC | PRLD | COM | $18,006,755 | 3,378,378 | SH | None |
| XENON PHARMACEUTICALS INC | XENE | COM | $16,116,120 | 267,000 | SH | None |
| C4 THERAPEUTICS INC | CCCC | COM STK | $15,775,171 | 3,377,981 | SH | None |
| KINIKSA PHARMACEUTICALS INTL | KNSA | ORD SHS CL A | $15,754,274 | 246,353 | SH | None |
| ORTHOPEDIATRICS CORP | KIDS | COM | $14,005,915 | 732,144 | SH | None |
| AVALYN PHARMACEUTICALS INC | AVLN | COM SHS | $13,793,480 | 419,000 | SH | None |
No matching rows. Clear the filter to see all records.
Largest 50 positions by reported value; the filing may contain more positions.
How amendments affect these holdings
This view uses 1 effective filing version(s). A restatement replaces the previous book; a new-holdings amendment adds positions. 1 positions lack a resolved ticker and 0 positions are put or call entries.
A 13F is a delayed quarterly snapshot of disclosed holdings. It is not a complete trade ledger and does not reveal every position in a manager's portfolio. Option values refer to the reported underlying position rather than a traded option premium.
Quarter end and public filing date
Use the filing's public availability date when constructing a historical observation. The quarter-end report period is earlier and cannot be substituted for when the public learned the holdings.